Feng Jia
Research Subjects
Research Interests
Feng Jia has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Shu Ruan
Department of Endocrinology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China
2 shared publications - Guan Liu
Department of Pharmacology, Hebei Medical University, Shijiazhuang City, Hebei Province, China
1 shared publication - Guang Zheng
International Institute for Earth System Science, Nanjing University, Nanjing 210023, China
1 shared publication - Hongmei Zhu
State Key Laboratory for Managing Biotic and Chemical Threats to the Quality and Safety of Agro-products, Institute of Quality and Standard for Agro-products, Zhejiang Academy of Agricultural Sciences, Hangzhou, 310021, Zhejiang, PR China
1 shared publication - Hongtao Guo
The First Affiliated Hospital of Henan University of Chinese Medicine,Henan,China
1 shared publication - Jianbo Li
Department of Pathology, Xiangya Changde Hospital, Changde 415000, Hunan, China
1 shared publication
Latest Publications
- 5 December 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 4999-5001
Weakened and Imbalanced Gene Expression of Rheumatoid Arthritis Patients with Qi-Blood-Deficiency Syndrome
Exploring the gene expression profile of rheumatoid arthritis (RA) patients with qi-blood-deficiency syndrome may shed light on the pathology of RA patients with qi-blood-deficiency syndrome in traditional Chinese medicine (TCM) towards precision medicine. In this study, GWAS (genome-wide association study), enrichment analysis, and visualizations were deployed on GSE205962 containing samples of RA patients with qi-blood-deficiency syndrome compared with healthy ones. As a result, more than half of differentially expressed genes were weakened/inhibited in RA patients with qi-blood-deficiency syndrome. To be enriched and demonstrated in KEGG RA-associated pathways, these pathways are all weakened and imbalanced with three gene groups: the activated, the inhibited, and the normal group. Besides, enrichment analysis also demonstrated that many signaling pathways are weakened and imbalanced by the development of RA with qi-blood-deficiency syndrome.
- 5 December 2023
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 4999-5001
Weakened and Imbalanced Gene Expression of Rheumatoid Arthritis Patients with Qi-Blood-Deficiency Syndrome
Exploring the gene expression profile of rheumatoid arthritis (RA) patients with qi-blood-deficiency syndrome may shed light on the pathology of RA patients with qi-blood-deficiency syndrome in traditional Chinese medicine (TCM) towards precision medicine. In this study, GWAS (genome-wide association study), enrichment analysis, and visualizations were deployed on GSE205962 containing samples of RA patients with qi-blood-deficiency syndrome compared with healthy ones. As a result, more than half of differentially expressed genes were weakened/inhibited in RA patients with qi-blood-deficiency syndrome. To be enriched and demonstrated in KEGG RA-associated pathways, these pathways are all weakened and imbalanced with three gene groups: the activated, the inhibited, and the normal group. Besides, enrichment analysis also demonstrated that many signaling pathways are weakened and imbalanced by the development of RA with qi-blood-deficiency syndrome.
- Open Access
- 1 November 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 8117-8125
In vitro and in vivo superior radiosensitizing effect of berbamine for head and neck squamous cell carcinoma
Background: Berbamine (BBM), one of the bis-benzylisoquinoline products isolated from Berberis amurensis, has been demonstrated for its anticancer effect against leukemia, breast cancer, liver cancer, etc. There are some studies focusing on the chemosensitization effect of BBM. However, there is no report about whether BBM could enhance the anticancer effect of radiation, which made us to explore the possible radiosensitization effect of BBM. Materials and methods: Here, in vitro cytotoxicity of BBM was evaluated on two kinds of head and neck squamous cancer cell lines. Clonogenic assay was performed to study the radiosensitization effect of BBM. Western blot was utilized to elucidate the possible mechanism underlying the radiosensitization effect. Results: BBM effectively inhibited the growth of two kinds of cancer cells in a time- and dose-dependent manner. Radiation plus BBM led to significantly more reduction of the colony-forming ability of cancer cells when compared with radiation alone. BBM plus radiation led to the most reduction of STAT3 phosphorylation, followed by the significant decrease of the ratio of Bax/Bcl-2. In vivo study demonstrated that the combinational administration of BBM and radiation generated the most significant tumor-delaying effect among all of the treatment regimens. Conclusion: We reported, in the current study, the potential role of BBM in not only treating cancer by itself but also offering a promising way to improve the efficacy of radiotherapy by inhibiting the activation of STAT3 and subsequently inducing the apoptosis of cancer.
- 1 November 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 8117-8125
Open AccessIn vitro and in vivo superior radiosensitizing effect of berbamine for head and neck squamous cell carcinoma
Background: Berbamine (BBM), one of the bis-benzylisoquinoline products isolated from Berberis amurensis, has been demonstrated for its anticancer effect against leukemia, breast cancer, liver cancer, etc. There are some studies focusing on the chemosensitization effect of BBM. However, there is no report about whether BBM could enhance the anticancer effect of radiation, which made us to explore the possible radiosensitization effect of BBM. Materials and methods: Here, in vitro cytotoxicity of BBM was evaluated on two kinds of head and neck squamous cancer cell lines. Clonogenic assay was performed to study the radiosensitization effect of BBM. Western blot was utilized to elucidate the possible mechanism underlying the radiosensitization effect. Results: BBM effectively inhibited the growth of two kinds of cancer cells in a time- and dose-dependent manner. Radiation plus BBM led to significantly more reduction of the colony-forming ability of cancer cells when compared with radiation alone. BBM plus radiation led to the most reduction of STAT3 phosphorylation, followed by the significant decrease of the ratio of Bax/Bcl-2. In vivo study demonstrated that the combinational administration of BBM and radiation generated the most significant tumor-delaying effect among all of the treatment regimens. Conclusion: We reported, in the current study, the potential role of BBM in not only treating cancer by itself but also offering a promising way to improve the efficacy of radiotherapy by inhibiting the activation of STAT3 and subsequently inducing the apoptosis of cancer.
- Open Access
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 8152526
Synergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
In our preliminary study, Berbamine (BA), one of the most commonly used traditional Chinese medicines, was effective in inducing the intracellular ROS levels. Since the regulation of cellular antioxidant capacity is crucial to the sensitivity of Ptx, it is feasible to propose that sensitizing cells to Ptx can be achieved through increasing the antioxidant capacity by codelivering BA. Cytotoxicity test demonstrates that either single or combinational treatment of BA and Ptx dose‐dependently inhibits the proliferation of U‐87 cells. Median‐effect analysis clearly proves the synergistic anticancer effect between BA and Ptx. Combinational treatment of both drugs induced more intracellular ROS generation than either of the drugs did. Cotreatment of NAC could partially reverse the ROS generation and ameliorate the cytotoxicity induced by BA plus Ptx. Moreover, sequential activation of ROS‐dependent phosphor‐Akt expression was dose‐dependently inhibited by the combinational application of BA and Ptx, which was more significantly effective than the single treatment of either BA or Ptx. Additionally, the coadministration of BA and Ptx shows the strongest tumor delaying effect in a U87 xenograft model, demonstrating the synergism between two drugs. Therefore, BA is a promising adjuvant to traditional chemotherapy, especially in combination with Ptx, to treat malignant glioma.
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 8152526
Open AccessSynergistic Antitumor Effects of Berbamine and Paclitaxel through ROS/Akt Pathway in Glioma Cells
In our preliminary study, Berbamine (BA), one of the most commonly used traditional Chinese medicines, was effective in inducing the intracellular ROS levels. Since the regulation of cellular antioxidant capacity is crucial to the sensitivity of Ptx, it is feasible to propose that sensitizing cells to Ptx can be achieved through increasing the antioxidant capacity by codelivering BA. Cytotoxicity test demonstrates that either single or combinational treatment of BA and Ptx dose‐dependently inhibits the proliferation of U‐87 cells. Median‐effect analysis clearly proves the synergistic anticancer effect between BA and Ptx. Combinational treatment of both drugs induced more intracellular ROS generation than either of the drugs did. Cotreatment of NAC could partially reverse the ROS generation and ameliorate the cytotoxicity induced by BA plus Ptx. Moreover, sequential activation of ROS‐dependent phosphor‐Akt expression was dose‐dependently inhibited by the combinational application of BA and Ptx, which was more significantly effective than the single treatment of either BA or Ptx. Additionally, the coadministration of BA and Ptx shows the strongest tumor delaying effect in a U87 xenograft model, demonstrating the synergism between two drugs. Therefore, BA is a promising adjuvant to traditional chemotherapy, especially in combination with Ptx, to treat malignant glioma.
- Open Access
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 9402615
Potential Antitumor Effect of Harmine in the Treatment of Thyroid Cancer
Thyroid cancer is one of the most common types of cancer in endocrine system. In latest studies, harmine has been proved to inhibit the growth of several cancers in vitro and in vivo. In the current study, we evaluated the in vitro and in vivo anticancer efficiency of harmine against thyroid cancer cell line TPC‐1. The in vitro cytotoxicity of harmine evaluated by XTT assay indicated that harmine suppressed the proliferation of TPC‐1 cells in a dose‐ and time‐dependent manner. Moreover, harmine dose‐dependently induced apoptosis of TPC‐1 cells through regulating the ratio of Bcl‐2/Bax. The colony forming ability of TPC‐1 cells was also time‐dependently inhibited by harmine. The inhibitory effects of harmine on migration and invasion of TPC‐1 cells were studied by wound scratching and Transwell assays. In vivo evaluation showed that harmine effectively inhibited the growth of thyroid cancer in a dose‐dependent manner in nude mice. Therefore, harmine might be a promising herbal medicine in the therapy of thyroid cancer and further efforts are needed to explore this therapeutic strategy.
- 1 January 2017
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2017 (1) , 9402615
Open AccessPotential Antitumor Effect of Harmine in the Treatment of Thyroid Cancer
Thyroid cancer is one of the most common types of cancer in endocrine system. In latest studies, harmine has been proved to inhibit the growth of several cancers in vitro and in vivo. In the current study, we evaluated the in vitro and in vivo anticancer efficiency of harmine against thyroid cancer cell line TPC‐1. The in vitro cytotoxicity of harmine evaluated by XTT assay indicated that harmine suppressed the proliferation of TPC‐1 cells in a dose‐ and time‐dependent manner. Moreover, harmine dose‐dependently induced apoptosis of TPC‐1 cells through regulating the ratio of Bcl‐2/Bax. The colony forming ability of TPC‐1 cells was also time‐dependently inhibited by harmine. The inhibitory effects of harmine on migration and invasion of TPC‐1 cells were studied by wound scratching and Transwell assays. In vivo evaluation showed that harmine effectively inhibited the growth of thyroid cancer in a dose‐dependent manner in nude mice. Therefore, harmine might be a promising herbal medicine in the therapy of thyroid cancer and further efforts are needed to explore this therapeutic strategy.